EUDA Health shares surge 11.07% intraday after subsidiary signs convertible loan agreement with Shenzhen Innate Immune for cGMP facility upgrades and stem cell therapy innovation center in China.

EUDA Health surged 11.07% intraday, as its subsidiary signed a convertible loan agreement with Shenzhen Innute Immune on January 13, 2026, for a two-phase investment of up to 6 million RMB to upgrade cGMP facilities, establishing a stem cell therapy innovation center and expanding its Chinese regenerative medicine platform. The company, an Asian non-invasive healthcare provider operating in Singapore, Malaysia, and China, specializes in stem cell therapy, CRISPR gene editing treatments, and health supplements.